| abstract |
The present invention is directed to the use of a therapy comprising administering cannagliflozin and phentermine for the treatment of obesity and obesity-related disorders; more particularly, the present invention is directed to a therapy to treat obesity, to promote weight loss and / or to suppress appetite; to treat, delay, slow progress and / or prevent metabolic disorders (including, for example, type 2 diabetes mellitus); to treat, delay, slow down progress and / or prevent kidney or fatty liver disorders (including, for example, NASH, HGNA, etc.); to treat, delay, slow down progress and / or prevent sleep disorders (including, for example, sleep apnea); to provide cardiovascular protection; to treat, delay, slow progress and / or prevent cardiovascular events (including major adverse cardiac events (ECAM), such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal stroke, peripheral artery disease, events aortic, hospitalization for congestive heart failure, etc.); and / or to extend or prolong longevity. |